A Case of Erythroplasia of Queyrat Treated with Imiquimod 5% Cream and Excision

Choi, Jee Woong; Choi, Mira; Cho, Kwang Hyun

doi:10.5021/ad.2009.21.4.419

Cited by 21 publications

(11 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Imiquimod, the only immune response modifier approved for clinical applications (as Aldara), has been successfully used to treat actinic keratosis and superficial basal cell carcinoma 7–9. In addition, the off‐label use of imiquimod cream has been effective in treating precancerous lesions and malignancies of several mucosal surfaces, including neoplasm of the vulvar epithelium, lip ulcers, erythroplasia of Queyrat, melanoma of the intraepithelial oral mucosa, and even oral leukoplakia 9–13. However, all of these procedures used the original (Aldara) cream to treat lesions in the oral cavity.…”

Section: Introductionmentioning

confidence: 99%

Development of Imiquimod-Loaded Mucoadhesive Films for Oral Dysplasia

Ramineni

Cunningham

Dziubla

et al. 2013

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Oral squamous dysplasia, which can usually be readily visualized as leukoplakia during an oral examination and confirmed by histology, is often considered a premalignant condition. Current treatments, however, focus on the final stages of disease, and treatments such as surgery can lead to postoperative disabilities. Hence, this study was designed to develop a noninvasive, mucoadhesive drug delivery system loaded with an immune response modifier, imiquimod, as treatment for precancerous dysplastic lesions. Blends of polyvinylpyrrolidone and carboxymethylcellulose were used to prepare mucoadhesive films that were backed with poly(ethylene-co-vinyl acetate). Because of the hydrophobic nature of imiquimod, four methods of loading (sonication, linoleic acid, 2-hydroxypropyl-β-cyclodextrin, and acetate buffer) were compared. The formation of imiquimod-cyclodextrin complexes and their solubility was studied by differential scanning calorimetry and phase solubility studies. All films achieved sustained release of drug for three hours except for those prepared by linoleic acid. The high solubility of imiquimod in acetate buffer facilitated high loading capability and greater release (68%) of drug than did the other formulations (approximately 40%). In summary, a noninvasive and local approach with the potential to treat precancerous lesions may be achieved by this described mucoadhesive drug delivery system.

show abstract

Section: Introductionmentioning

confidence: 99%

Development of Imiquimod-Loaded Mucoadhesive Films for Oral Dysplasia

Ramineni

Cunningham

Dziubla

et al. 2013

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

show abstract

“…In our case study, topical therapy with imiquimod 5% effectively treated the patient's EQ as evidenced clinically and by follow-up OCT. Several other case reports have also demonstrated the successful treatment of EQ with imiquimod 5% both in the presence and absence of HPV type 16 infection [3,16,17,18,19]. The results of these case reports together suggest that both the antiviral and antitumour effects of imiquimod are important in its ability to treat EQ.…”

Section: Discussionmentioning

confidence: 73%

Optical Coherence Tomography Imaging of Erythroplasia of Queyrat and Treatment with Imiquimod 5% Cream: A Case Report

Schmitz¹,

Bierhoff

Dirschka³

2013

Dermatology

View full text Add to dashboard Cite

Lesion biopsy is currently used to diagnose erythroplasia of Queyrat (EQ), a rare squamous cell carcinoma in situ of the glans penis, or to determine whether the cancer is invasive, although the results only apply to the area from which the biopsy is taken. In this case report, we illustrate for the first time the use of optical coherence tomography (OCT) in imaging the entire lesion in a patient with EQ. The results confirmed that the patient had in situ rather than invasive carcinoma. Consequently, non-invasive treatment with imiquimod 5%, a topical immunomodulator with antitumour and antiviral properties, was initiated. Excellent clinical results were observed 4 weeks after the patient had been treated with imiquimod 5% three times a week for 8 weeks, which were confirmed using OCT imaging. One year later, there was still no evidence of pathology either clinically or via OCT imaging. OCT imaging should be used in conjunction with biopsy evaluation in the diagnostic work-up of EQ. Imiquimod 5% is a suitable treatment for patients with EQ, and the treatment response can be evaluated using OCT.

show abstract

“…The etiology of EQ is linked to HPV infection (8,16,39 and 51 subtypes), but risk factors have also been described (social and cultural habits, hygienic procedures, religious practices, heat, friction, trauma and co-infection with human papillomavirus type 8. [7][8][9] EQ is characterized clinically by the presence of unique or multiple well-demarcated, velvety, shiny, intense red plaques on the glans penis, the foreskin, or the urethral meatus of elderly male patients. 7 These are clinical features in favor of EQ.…”

Section: Case Reportmentioning

confidence: 99%

Erythroplasia of Queyrat Treated with 5% Imiquimod Cream — Case Report Emphasizing the Role of Human Papilloma Virus Testing in a Clinical Setting

Chiriac¹,

Brzeziński²,

Podoleanu³

et al. 2017

Journal of Interdisciplinary Medicine

View full text Add to dashboard Cite

Background: Anogenital premalignancies and malignancies often affect females and males, and human papillomavirus infection plays a crucial role in their etiopathogenesis. These lesions are very important and represent an immense public health burden. Case presentation: A 78-year-old Caucasian male presented to the Dermatology Unit for persistent, slowly progressing, well-demarcated, erythematous plaques on the glans penis, observed by the patient 18 months prior to the consultation. Variable topical treatments were applied, with no improvement and with the denial of a punch biopsy. A clinical diagnosis of erythroplasia of Queyrat was established and the test for HPV revealed an association with subtype 16 (which excluded other benign inflammatory conditions). Positive results were obtained after 4 weeks of topical application of 5% imiquimod cream, once daily, 5 times a week. Conclusion: Erythroplasia of Queyrat should be diagnosed in a non-compliant patient based on the clinical picture and HPV testing even in the absence of a biopsy, and a non-surgical treatment should be initiated immediately.

show abstract

A Case of Erythroplasia of Queyrat Treated with Imiquimod 5% Cream and Excision

Cited by 21 publications

References 11 publications

Development of Imiquimod-Loaded Mucoadhesive Films for Oral Dysplasia

Development of Imiquimod-Loaded Mucoadhesive Films for Oral Dysplasia

Optical Coherence Tomography Imaging of Erythroplasia of Queyrat and Treatment with Imiquimod 5% Cream: A Case Report

Erythroplasia of Queyrat Treated with 5% Imiquimod Cream — Case Report Emphasizing the Role of Human Papilloma Virus Testing in a Clinical Setting

Contact Info

Product

Resources

About